AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30209353 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (180 mg)
Number of subjects: 16
Study 30209353 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin + Fish Oil (1.2 g)
Number of subjects: 16
Study 30209353 — intervention group
Group type: COMPARATOR
Intervention: Fish Oil (1.2 g)
Number of subjects: 16
Study 30209353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27228651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy
Number of subjects: 103
Study 27228651 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 103
Study 25122648 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d of EPA+DHA from fish oil (FO)
Number of subjects: 332
Study 25122648 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g/d of EPA+DHA from fish oil (FO)
Number of subjects: 332
Study 25122648 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g/d of EPA+DHA from fish oil (FO)
Number of subjects: 332
Study 25122648 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PSs) with varying amounts of FO
Number of subjects: 332
Study 25122648 — intervention group
Group type: COMPARATOR
Intervention: Control spread (no PSs, no FO)
Number of subjects: 332
Study 22209059 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 55
Study 21531577 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil treatment
Number of subjects: 811
Study 18082107 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated patients with schizophrenia
Number of subjects: 28
Study 18082107 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 28
Study 15542572 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handgrip exercise at 30% of maximal voluntary contraction for 3 minutes
Number of subjects: 9
Study 15542572 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthandgrip ischemia for 3 minutes
Number of subjects: 9
Study 15542572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic task for 3 minutes
Number of subjects: 9
Study 12062463 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal methadone treatment with daily INH DOPT (n=35)
Number of subjects: 111
Study 12062463 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard methadone treatment with daily INH DOPT (n=37)
Number of subjects: 111
Study 12062463 — intervention group
Group type: COMPARATOR
Intervention: Routine care referral to TB clinic for monthly INH supplies without DOPT and without methadone treatment (n=39)
Number of subjects: 111
Study 12062463 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of preventive therapy
Number of subjects: 111
Study 11280842 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education
Number of subjects: 39
Study 11280842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 39
Study 8533541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.11 mg/kg
Number of subjects: 20
Study 8533541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.15 mg/kg
Number of subjects: 20
Study 8533541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.19 mg/kg
Number of subjects: 20
Study 8533541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (all doses)
Number of subjects: 20
Study 2170852 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BC-PS
Number of subjects: 8
Study 2170852 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg BC-PS
Number of subjects: 8
Study 2170852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 626722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 80
Study 626722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30681791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 766
Study 30681791 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 766
Study 30257292 — intervention group
Group type: EXPERIMENTAL
Intervention: O-Arm
Number of subjects: 22
Study 30257292 — intervention group
Group type: EXPERIMENTAL
Intervention: AIRO
Number of subjects: 22
Study 27192505 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) membrane
Number of subjects: 60
Study 27192505 — intervention group
Group type: COMPARATOR
Intervention: Paper patch technique
Number of subjects: 60
Study 24568751 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 positive activities
Number of subjects: 417
Study 24568751 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 positive activities
Number of subjects: 417
Study 24568751 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 positive activities
Number of subjects: 417
Study 24568751 — intervention group
Group type: COMPARATOR
Intervention: 0 positive activities (control group)
Number of subjects: 417
Study 22393084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab monotherapy (840 mg loading dose, then 420 mg every 3 weeks)
Number of subjects: 29
Study 22393084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pertuzumab and trastuzumab (pertuzumab at the same dose, trastuzumab 4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks)
Number of subjects: 29
Study 20642918 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking epidural analgesia with 15 ml of 0.1% Bupivacaine + 0.5 mg/ml Tramadol
Number of subjects: 100
Study 20642918 — intervention group
Group type: COMPARATOR
Intervention: Injection Nalbuphine 10 mg intramuscular (control group A)
Number of subjects: 100
Study 17936185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 3200 IU/day for 20 weeks
Number of subjects: 0
Study 17936185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E doses of 1600 IU and 3200 IU/day for 16 weeks
Number of subjects: 0
Study 15009332 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music during waiting period
Number of subjects: 113
Study 15009332 — intervention group
Group type: COMPARATOR
Intervention: Usual relaxing activities in waiting room
Number of subjects: 113
Study 11306897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 0
Study 11306897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg t.i.d.
Number of subjects: 0
Study 11306897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9853647 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 32
Study 9853647 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 32
Study 9853647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 32
Study 7857844 — intervention group
Group type: COMPARATOR
Intervention: Single freeze-thaw cycle
Number of subjects: 300
Study 7857844 — intervention group
Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle
Number of subjects: 300
Study 7857844 — intervention group
Group type: COMPARATOR
Intervention: Single freeze-thaw cycle for plantar warts
Number of subjects: 300
Study 7857844 — intervention group
Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle for plantar warts
Number of subjects: 300
Study 2504140 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight nasogastric nutritional supplementation
Number of subjects: 11
Study 2504140 — intervention group
Group type: COMPARATOR
Intervention: Control (no nasogastric feeding)
Number of subjects: 11
Study 1099449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta‐9‐tetrahydrocannabinol
Number of subjects: 20
Study 1099449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30784012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 100,000 IU per week
Number of subjects: 94
Study 30784012 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol 40,000 IU per week
Number of subjects: 94
Study 30311701 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks
Number of subjects: 489
Study 30311701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (deferred treatment)
Number of subjects: 489
Study 28598760 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU group, Mepilex)
Number of subjects: 98
Study 28598760 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane with silicone membrane (PUSM group, Mepilex border)
Number of subjects: 98
Study 28598760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent, breathable film (TBF group, Mepitel film)
Number of subjects: 98
Study 28598760 — intervention group
Group type: COMPARATOR
Intervention: Cotton gauze dressings (CG group)
Number of subjects: 98
Study 25649881 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) + carbocysteine (S-CMC)
Number of subjects: 0
Study 25649881 — intervention group
Group type: COMPARATOR
Intervention: S-CMC
Number of subjects: 0
Study 24746035 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT), 8 sessions
Number of subjects: 16
Study 24746035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 22112605 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50
Study 22112605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification (LSM)
Number of subjects: 50
Study 22112605 — intervention group
Group type: COMPARATOR
Intervention: No LSM (Control)
Number of subjects: 50
Study 22112605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 50
Study 20192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding hands widened
Number of subjects: 0
Study 20192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm positions larger than shoulder width
Number of subjects: 0
Study 20192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a large object or wearing a large object
Number of subjects: 0
Study 17389554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg oral dose
Number of subjects: 57
Study 16107035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu Yang Huan Wu Soup (BYHWS)
Number of subjects: 48
Study 16107035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Mai Soup (TMS)
Number of subjects: 48
Study 16107035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication affecting coagulation)
Number of subjects: 48
Study 11826641 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (HA) 6 mg, injected in the upper compartments of the involved TMJs, three to four injections as one course.
Number of subjects: 67
Study 11826641 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (PS) 12.5 mg, injected once a week, three to four injections as one course.
Number of subjects: 67
Study 10599905 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic doxycycline at a dosage of 100 mg/day for 14 days
Number of subjects: 20
Study 10599905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no doxycycline administration)
Number of subjects: 20
Study 8943436 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally compressed echocardiographic images (JPEG algorithm at 20:1 compression)
Number of subjects: 179
Study 8943436 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncompressed digital images
Number of subjects: 179
Study 8943436 — intervention group
Group type: COMPARATOR
Intervention: S-VHS images (control)
Number of subjects: 179
Study 1928815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline for six months
Number of subjects: 40
Study 1928815 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 40
Study 6357929 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg daily)
Number of subjects: 14
Study 6357929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprindine (150 mg daily for the first two days and 50 mg every 12 hours subsequently)
Number of subjects: 14
Study 6357929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31008867 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided blood product transfusion
Number of subjects: 60
Study 31008867 — intervention group
Group type: COMPARATOR
Intervention: Conventional transfusion
Number of subjects: 60
Study 28889781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine cleaning
Number of subjects: 206
Study 28889781 — intervention group
Group type: COMPARATOR
Intervention: Omission of cleaning
Number of subjects: 206
Study 28463040 — intervention group
Group type: COMPARATOR
Intervention: UD‐DPI (400 μg, 0.8% lactose blend)
Number of subjects: 0
Study 28463040 — intervention group
Group type: COMPARATOR
Intervention: UD‐DPI (0.8% lactose blend)
Number of subjects: 0
Study 25586959 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI and EEG data acquisition during contextual cueing task
Number of subjects: 0
Study 25586959 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG data recorded in isolation one week later
Number of subjects: 0
Study 23727501 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led intervention (ILI)
Number of subjects: 71
Study 23727501 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 71
Study 21849595 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal (dried meat, butter, and white bread)
Number of subjects: 8
Study 21849595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid component (butter alone)
Number of subjects: 8
Study 21849595 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein component (dried meat alone)
Number of subjects: 8
Study 21849595 — intervention group
Group type: COMPARATOR
Intervention: Control (no meal)
Number of subjects: 8
Study 19721147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing prosthesis
Number of subjects: 120
Study 19721147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 120
Study 17251482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg)
Number of subjects: 15
Study 17251482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (60 mug)
Number of subjects: 15
Study 17251482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14698543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (V) 25mg/m2 IV infusion + Gemcitabine (G) 1000 mg/m2 IV infusion on days 1 and 8 of each 21-day cycle
Number of subjects: 50
Study 14698543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (V) and Gemcitabine (G)
Number of subjects: 50
Study 12790969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% GTN
Number of subjects: 48
Study 12790969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN
Number of subjects: 48
Study 12790969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% GTN
Number of subjects: 48
Study 12790969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9562938 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25-75 mg/day)
Number of subjects: 52
Study 9562938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10-20 mg/day)
Number of subjects: 52
Study 9562938 — intervention group
Group type: COMPARATOR
Intervention: Historical sample (no ACE-inhibitor therapy)
Number of subjects: 52
Study 7698127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin
Number of subjects: 140
Study 7698127 — intervention group
Group type: EXPERIMENTAL
Intervention: High low density lipoprotein cholesterol
Number of subjects: 140
Study 7698127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high density lipoprotein cholesterol
Number of subjects: 140
Study 7698127 — intervention group
Group type: COMPARATOR
Intervention: Ferritin
Number of subjects: 140
Study 3052769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 221
Study 3052769 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 221
Study 30870225 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine monotherapy for 8 cycles
Number of subjects: 233
Study 30870225 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 233
Study 28438924 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin, rifampin, and isoniazid for 4 months (pyrazinamide for the first 2 months)
Number of subjects: 1686
Study 28438924 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (rifampin and isoniazid for 6 months; pyrazinamide and ethambutol for 2 months)
Number of subjects: 1686
Study 25088963 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60mg subcutaneous injections twice yearly
Number of subjects: 80
Study 25088963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22465206 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 94
Study 22465206 — intervention group
Group type: COMPARATOR
Intervention: Global support scores
Number of subjects: 94
Study 22013794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-reducing red rice minute powder (LRRMP) 175 mg/pill, 2 pills daily for 6 months
Number of subjects: 60
Study 22013794 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang Capsule 300 mg/pill, 2 pills daily for 6 months
Number of subjects: 60
Study 22013794 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin Tablet 20 mg/tablet, 1 tablet daily for 6 months
Number of subjects: 60
Study 19079839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soya diet (two daily servings with 3035mg isoflavones per serving)
Number of subjects: 24
Study 19079839 — intervention group
Group type: COMPARATOR
Intervention: Low-soya diet
Number of subjects: 24
Study 19079839 — intervention group
Group type: EXPERIMENTAL
Intervention: High soya intake early in life
Number of subjects: 24
Study 19079839 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya intake during adulthood
Number of subjects: 24
Study 19079839 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP‐1b, adiponectin, IL‐6 and CRP
Number of subjects: 24
Study 16697324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 247
Study 16697324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 mg
Number of subjects: 247
Study 16697324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (open-label)
Number of subjects: 247
Study 16697324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 16091234 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pharmacologic interventions for painful HIV neuropathy, including experimental agents studied in recent and ongoing clinical trials.
Number of subjects: 0
Study 11306776 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine esterase 0.005 unit/kg x 2 times/day
Number of subjects: 50
Study 11306776 — intervention group
Group type: COMPARATOR
Intervention: Heparin (activated partial thromboplastin time 2‐3 times of baseline value)
Number of subjects: 50
Study 9325477 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (BSR) 30 mg daily for 12 weeks
Number of subjects: 58
Study 9325477 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AML) 50 mg daily for 12 weeks
Number of subjects: 58
Study 7524296 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 100 mg/day
Number of subjects: 48
Study 7524296 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 48
Study 7524296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2573325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/d
Number of subjects: 120
Study 2573325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/d
Number of subjects: 120
Study 2573325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 239414 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 15
Study 239414 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (25 mg)
Number of subjects: 15
Study 239414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30566611 — intervention group
Group type: EXPERIMENTAL
Intervention: Core model (age, hypertension, World Federation of Neurosurgical Societies grade)
Number of subjects: 338
Study 30566611 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging model (aneurysm size/location, Fisher score)
Number of subjects: 338
Study 30566611 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model (Core + neuroimaging + treatment type)
Number of subjects: 338
Study 30566611 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall models
Number of subjects: 338
Study 30540224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic-concordance condition (Turkish minority physician)
Number of subjects: 256
Study 30540224 — intervention group
Group type: COMPARATOR
Intervention: Ethnic-discordance condition (German majority physician)
Number of subjects: 256
Study 27911344 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 280
Study 27911344 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 280
Study 25361548 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (TOMO)
Number of subjects: 20
Study 25361548 — intervention group
Group type: COMPARATOR
Intervention: Step-and-shoot IMRT (SSIMRT)
Number of subjects: 20
Study 24295464 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually supported self‐monitoring using adapted DBT diary cards (DC)
Number of subjects: 0
Study 24295464 — intervention group
Group type: EXPERIMENTAL
Intervention: Group‐based DBT
Number of subjects: 0
Study 21261966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team consultation lasting up to one hour with up to four case-specific health care professionals.
Number of subjects: 94
Study 21261966 — intervention group
Group type: COMPARATOR
Intervention: Normal primary care services (Control).
Number of subjects: 94
Study 21261966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team consultation.
Number of subjects: 94